-transparent.png){kind=logo}
In a double-blind quadruple cross-over study the effect of a new alpha-glucosidase inhibitor (BAY g 5421) on postprandial blood glucose, serum insulin, and serum triglyceride increases was tested in 24 male healthy volunteers. They received before a standardized breakfast 50, 100, or 200 mg of BAY g 5421 or a placebo per os. The dose-time-response relationships were calculated and the drug tolerance was assessed. There was a statistically significant inhibition of the postprandial increases of the blood glucose, serum insulin, and triglyceride values. Further analysis showed no dose-dependent effect of the drug on the blood glucose values, whereas the serum insulin and triglyceride values were affected in a dose-dependent fashion. The maximal inhibitory effect on the serum insulin levels occurred 69 min after breakfast and on the serum triglyceride levels 104 min after breakfast. One hundred and 200 mg of BAY g 5421 were equally inhibitory-effective on the serum insulin levels, whereas the highest dose used was markedly more effective on serum triglyceride values than lower doses. Based on these results, a dosage of 100--200 mg of BAY g 5421/meal is recommended for clinical trials in metabolic diseases.
I Hillebrand, and
K Boehme, and
G Frank, and
H Fink, and
P Berchtold
January 1985,
Nagoya journal of medical science,
I Hillebrand, and
K Boehme, and
G Frank, and
H Fink, and
P Berchtold
May 1999,
American journal of veterinary research,
I Hillebrand, and
K Boehme, and
G Frank, and
H Fink, and
P Berchtold
January 1987,
International journal of obesity,
I Hillebrand, and
K Boehme, and
G Frank, and
H Fink, and
P Berchtold
January 1982,
Digestion,
I Hillebrand, and
K Boehme, and
G Frank, and
H Fink, and
P Berchtold
May 1981,
Diabetologia,
I Hillebrand, and
K Boehme, and
G Frank, and
H Fink, and
P Berchtold
November 1979,
Diabetologia,
I Hillebrand, and
K Boehme, and
G Frank, and
H Fink, and
P Berchtold
January 1980,
Arzneimittel-Forschung,
I Hillebrand, and
K Boehme, and
G Frank, and
H Fink, and
P Berchtold
July 1982,
Metabolism: clinical and experimental,
I Hillebrand, and
K Boehme, and
G Frank, and
H Fink, and
P Berchtold
January 1986,
European journal of clinical pharmacology,
I Hillebrand, and
K Boehme, and
G Frank, and
H Fink, and
P Berchtold
July 1983,
Pharmacology, biochemistry, and behavior,
